6.23
-0.37 (-5.64%)
| Previous Close | 6.60 |
| Open | 6.67 |
| Volume | 1,470,910 |
| Avg. Volume (3M) | 814,449 |
| Market Cap | 368,024,288 |
| Price / Earnings (Forward) | 103.09 |
| Price / Sales | 1.49 |
| Price / Book | 0.680 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -21.98% |
| Operating Margin (TTM) | -81.99% |
| Diluted EPS (TTM) | -0.760 |
| Quarterly Revenue Growth (YOY) | 5.40% |
| Total Debt/Equity (MRQ) | 2.30% |
| Current Ratio (MRQ) | 3.92 |
| Operating Cash Flow (TTM) | -56.47 M |
| Levered Free Cash Flow (TTM) | -41.71 M |
| Return on Assets (TTM) | -7.05% |
| Return on Equity (TTM) | -8.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vanda Pharmaceuticals Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.16% |
| % Held by Institutions | 78.96% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (HC Wainwright & Co., 221.16%) | Buy |
| Median | 11.00 (76.64%) | |
| Low | 11.00 (Cantor Fitzgerald, 76.64%) | Buy |
| 11.00 (B. Riley Securities, 76.64%) | Buy | |
| Average | 14.00 (124.81%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.63 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 19 Nov 2025 | 20.00 (221.16%) | Buy | 5.14 |
| B. Riley Securities | 05 Nov 2025 | 11.00 (76.64%) | Buy | 4.44 |
| Cantor Fitzgerald | 30 Oct 2025 | 11.00 (76.64%) | Buy | 4.32 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |